Table 3.
An overview of cancer patients’ clinical outcome after treatment with c-MET inhibitors within clinical studies.
| TUMOR TYPE | PHASE | DRUG | RESPONSE RATE | PFS | OS | REF. |
|---|---|---|---|---|---|---|
| NSCLC | III | Tivantinib + erlotinib vs. placebo + erlotinib | 8.4% vs. 6.5% | 2.9 mo vs. 2 mo | 12.9 mo vs. 11.2 mo | 68 |
| NSCLC | III | Onartuzumab + erlotinib vs. placebo + erlotinib | NA | 2.6 mo vs. 2.7 mo | 6.8 mo vs. 9.1 mo | 65 |
| NSCLC | III | Crizotinib vs. CT (pemetrexed or docetaxel) | 65% vs. 20% | 7.7 mo vs. 3 mo | 20.3 mo vs. 22.8 mo | 90 |
| NSCLC | III | Crizotinib vs. CT (pemetrexed + cisplatin or carboplatin) | 74 vs. 45% | 10.9 mo vs. 7 mo | NA | 94 |
| NSCLC | II | Erlotinib vs. cabozantinib vs. erlotinib + cabozantinib | NA | 1.9 mo vs. 3.9 mo vs. 4.1 mo | 4.0 mo vs. na vs. na | 96 |
| NSCLC | II | Ficlatuzumab + geftinib vs. geftinib | 43% vs. 40% | 5.6 mo vs. 4.7 mo | NA | 170 |
| RCC | II | Foretinib | 13.5% | 9.3 mo | NA | 106 |
| RCC | II | Rilotumumab 10 mg vs. 20 mg | 2.5% vs. 0% | 3.7 mo vs. 2.0 mo | 14.9 mo vs. 17.6 mo | 171 |
| RCC | I | Cabozantinib | PR 28%, SD 52% | 12.9 mo | 15 mo | 172 |
| RCC | III | Cabozantinib + rosiglitazone | 28% | 14.7 mo | NA | 173 |
| Solid tumors (mainly RCC and colorectal cancer) | I | Savolitinib | 3 RCC pts achieved PR, 1 pt CRC achieved PR | NA | NA | 72 |
| Prostate cancer | III | Cabozantinib vs. prednisone | 41% vs. 3% | 5.5 mo vs. 2.8 mo | 11 mo vs. 9.8 mo | 174 |
| Prostate cancer | II | Mitoxantrone + prednisone + rilotumumab vs. mitoxantrone + prednisone + placebo | 11% vs. 14% | 3.0 mo vs. 2.9 mo | 12.2 mo vs. 11.1 mo | 175 |
| Colorectal cancer | I/II | Cetuximab + irinotecan + tivantinib vs. cetuximab + irinotecan + placebo | 45% vs. 33% | 8.3 mo vs. 7.3 mo | NA | 176 |
| Colorectal cancer | I/II | Panitumumab + rilotumumab vs. panitumumab + ganitumumab vs. panitumumab + placebo | 31% vs. 22% vs. 21% | 5.2 mo vs. 5.3 mo vs. 3.7 mo | NA | 177 |
| Esophagogastric cancer | II | Epirubicin + cisplatin + xeloda + rilotumumab vs. epirubicin + cisplatin + xeloda + placebo | 38% vs. 24% | 5.6 mo vs. 4.2 mo | 11.1 mo vs. 8.9 mo | 178 |
| Gatric cancer | II | Forentinib (intermittent vs. daily cohort) | 0% vs. 0% | 1.7 mo vs. 1.8 mo | 7.4 mo vs. 4.3 mo | 179 |
| Hepatocellular cancer | II | Tivantinib vs. placebo | 1% vs. 0% | 1.5 mo vs. 1.4 mo | 6.6 vs. 6.2 mo | 153 |
| Hepatocellular cancer | II | Cabozantinib | 5% | 4.4 mo | 15.1 mo | 180 |
| Hepatocellular cancer | I/II | Foretinib | 24% | 4.2 mo | NA | 181 |
| Uveal melanoma | II | Cabozantinib | NA | 4.8 mo | 12.6 mo | 182 |
| Melanoma | II | Cabozantinib | PR 5%, SD 57% | 4.2 mo | NA | 183 |
| Breast cancer | II | Cabozantinib | PR 14%, SD 57% | 4.3 mo | NA | 184 |
| HNSCC | II | Foretinib | NA | 3.65 mo | 5.59 mo | 185 |
| Germ cell tumors | II | Tivantinib | PR 0%, SD 20% | 1.0 mo | 6.0 mo | 186 |
| Glioblastoma | II | Rilotumumab (10 vs. 20 mg/kg) | 0% vs. 0% | 4.1 mo vs. 4.3 mo | 6.5 mo vs. 5.4 mo | 144 |
| Sarcoma | II | Crizotinib | PR 0%, SD 58.3%, PD 41.7% | 5.25 mo | NA | 187 |
| Thyroid cancer | III | Cabozantinib vs. placebo | 28% vs. 0% | 11.2 mo vs. 4.0 mo | NA | 188 |
Abbreviations: HNSCC, head and neck squamous cell carcinoma; mo, months; NA, not available; NSCLC, non small cell lung cancer; OS, overall survival; PFS, progression free survival; PR, partial response; RCC, renal cancer carcinoma; SD, stable disease.